<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Challenges in modern medicine</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.52575/2687-0940-2022-45-3-237-252</article-id><article-id pub-id-type="publisher-id">120</article-id><article-categories><subj-group subj-group-type="heading"><subject>INTERNAL DISEASES</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Mechanisms of Development of Heart Failure in Chronic Kidney Disease&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Mechanisms of Development of Heart Failure in Chronic Kidney Disease&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Efremova</surname><given-names>Olga A.</given-names></name><name xml:lang="en"><surname>Efremova</surname><given-names>Olga A.</given-names></name></name-alternatives><email>efremova@bsu.edu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Kamyshnikova</surname><given-names>Lyudmila A.</given-names></name><name xml:lang="en"><surname>Kamyshnikova</surname><given-names>Lyudmila A.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Obolonkova</surname><given-names>Natalya I.</given-names></name><name xml:lang="en"><surname>Obolonkova</surname><given-names>Natalya I.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Sviridova</surname><given-names>Maria S.</given-names></name><name xml:lang="en"><surname>Sviridova</surname><given-names>Maria S.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Golivets</surname><given-names>Tatyana P.</given-names></name><name xml:lang="en"><surname>Golivets</surname><given-names>Tatyana P.</given-names></name></name-alternatives><email>golivets@ya.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Khamnagadaev</surname><given-names>Igor I.</given-names></name><name xml:lang="en"><surname>Khamnagadaev</surname><given-names>Igor I.</given-names></name></name-alternatives><email>efremova@bsu.ru</email></contrib></contrib-group><pub-date pub-type="epub"><year>2022</year></pub-date><volume>45</volume><issue>3</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2022/3/237-252.pdf" /><abstract xml:lang="ru"><p>Heart failure is widespread and associated with a high mortality rate in chronic kidney disease. However, the pathophysiology of cardiac dysfunction in chronic kidney disease, especially in latent renal disease, is poorly understood. Disability and high mortality in patients with cardiorenal syndrome dictate the need to study the mechanisms of development of heart failure in chronic kidney disease. This literature search review used PubMed and Google Scholar to identify the mechanisms of heart failure in chronic kidney disease. The study of scientific data over the past 5 years has shown that cardiorenal syndrome, which has a complex and multifactorial pathophysiology, is a clinical problem. Diagnostic, prognostic, and therapeutic measures for cardiorenal syndrome are limited. Modern pharmacological methods of treatment are effective, but insufficient to satisfactorily influence or mitigate the progression of cardiorenal syndrome, therefore, the discovery of new drugs and new therapeutic strategies for cardiorenal syndrome is a high priority task. Treatment of patients with cardiorenal syndrome should be comprehensive and continuous, aimed at eliminating physical and psychosocial symptoms.</p></abstract><trans-abstract xml:lang="en"><p>Heart failure is widespread and associated with a high mortality rate in chronic kidney disease. However, the pathophysiology of cardiac dysfunction in chronic kidney disease, especially in latent renal disease, is poorly understood. Disability and high mortality in patients with cardiorenal syndrome dictate the need to study the mechanisms of development of heart failure in chronic kidney disease. This literature search review used PubMed and Google Scholar to identify the mechanisms of heart failure in chronic kidney disease. The study of scientific data over the past 5 years has shown that cardiorenal syndrome, which has a complex and multifactorial pathophysiology, is a clinical problem. Diagnostic, prognostic, and therapeutic measures for cardiorenal syndrome are limited. Modern pharmacological methods of treatment are effective, but insufficient to satisfactorily influence or mitigate the progression of cardiorenal syndrome, therefore, the discovery of new drugs and new therapeutic strategies for cardiorenal syndrome is a high priority task. Treatment of patients with cardiorenal syndrome should be comprehensive and continuous, aimed at eliminating physical and psychosocial symptoms.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>chronic heart failure</kwd><kwd>cardiorenal syndrome</kwd><kwd>pathogenesis</kwd><kwd>comorbid pathology</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>cardiorenal syndrome</kwd><kwd>pathogenesis</kwd><kwd>comorbid pathology</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Agrawal A., Naranjo M., Kanjanahattakij N., Rangaswami J., Gupta Sh. 2019. Cardiorenal syndrome in heart failure with preserved ejection fraction&amp;ndash;an under-recognized clinical entity. Heart Failure Reviews. 24: 421&amp;ndash;437. doi: 10.1007/s10741-018-09768-9.</mixed-citation></ref><ref id="B2"><mixed-citation>Barrows I.R., Ramezani A., Raj D.S. 2019. Inflamation, Immuninty, and Oxidative Stress in Hypertension-Partners in Crime? Advances in Chronic Kidney Disease. 26: 122&amp;ndash;130. doi: 10.1053/j.ackd.2019.03.001.</mixed-citation></ref><ref id="B3"><mixed-citation>Black A.P., Anjos J.S., Cardozo L., Carmo F.L., Dolenga C.J., Nakao L.S., de Carvalho Ferreira D., Rosado A., Carraro Eduardo J.C., Mafra D. 2018. Does low-protein diet influence theuremic toxin serum levels from the gut microbiota in nondialysischronic kidney disease patients? Journal of Renal Nutrition. 28: 208&amp;ndash;214. doi: 10.1053/j.jrn.2017.11.007.</mixed-citation></ref><ref id="B4"><mixed-citation>Caio-Silva W., da Silva Dias D., Junho C.V.C., Panico K., Neres-Santos R.S., Pelegrino M.T., Pieretti&amp;nbsp;J.C., Seabra A.B., De Angelis K., Carneiro-Ramos M.S. 2020. Characterization of the Oxidative Stress in Renal Ischemia/Reperfusion-Induced Cardiorenal Syndrome Type 3. Bio Med Research International. 2020: 1605358. doi: 10.1155/2020/1605358.</mixed-citation></ref><ref id="B5"><mixed-citation>Cha R.H., Kang S.W., Park C.W., Cha D.R., Na K.Y., Kim S.G., Yoon S.A., Han S.Y., Chang J.H., Park&amp;nbsp;S.K., Lim C.S., Kim Y.S. 2016. A randomized, controlled trial of oral intestinal sor-bent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clinical Journal of the American Society of Nephrology. 11: 559&amp;ndash;567. doi: 10.2215/CJN.12011214.</mixed-citation></ref><ref id="B6"><mixed-citation>Chacon-Portillo M.A., Acharya T., Janardhanan R. 2021. Imaging in heart failure with preserved ejection fraction: insights into echocardiography and cardiac magnetic resonance imaging. Rev. Cardiovascular Medicine. 22 (1): 11&amp;ndash;24. doi: 10.31083/j.rcm.2021.01.134.</mixed-citation></ref><ref id="B7"><mixed-citation>Chen Y., Zheng Y., Iyer S.R., Harders G.E., Pan S., Chen H.H., Ichiki T., Burnett J.C. Jr., Sangaralingham S.J. 2019. C53: A novel particulate guanylyl cyclaseB receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. Journal of Molecular and Cellular Cardiology. 130: 140&amp;ndash;150. C53: doi: 10.1016/j.yjmcc.2019.03.024.</mixed-citation></ref><ref id="B8"><mixed-citation>Chinnappa S., White E., Lewis N., Baldo O., Tu Y.K., Glorieux G., Vanholder R., El Nahas M., Mooney&amp;nbsp;A. 2018. Early and asymptomatic cardiac dysfunction in chronic kidney disease, Nephrology Dialysis Transplantation. 33: 450&amp;ndash;458. doi: 10.1093/ndt/gfx064.</mixed-citation></ref><ref id="B9"><mixed-citation>Chrysohoou C., Bougatsos G., Magkas N., Skoumas J., Kapota A., Kopelias J., Bliouras N., Tsioufis K., Petras D., Tousoulis D. 2020. Peritoneal dialysis as a therapeutic solution in elderly patients with cardiorenal syndrome and heart failure: A case-series report. The Hellenic Journal of Cardiology. 61 (2): 73&amp;ndash;77. doi: 10.1016/j.hjc.2019.04.010.</mixed-citation></ref><ref id="B10"><mixed-citation>Chu S., Mao X., Guo H., Wang L., Li Z., Zhang Y., Wang Y., Wang H., Zhang X., Peng W. 2017. Indoxyl sulfate potentiates endothelial dysfunction via reciprocal role for reactive oxygen species and RhoA/ROCK signaling in 5/6 nephrectomized rats. Free Radical Research. 51: 237&amp;ndash;252. doi: 10.1080/10715762.2017.1296575.</mixed-citation></ref><ref id="B11"><mixed-citation>Clegg D.J., Cody M., Palmer B.F. 2017. Challenges in treating cardio-vascular disease: Restricting sodium and managing hyperkalemia. Mayo Clinic Proceedings. 92: 1248&amp;ndash;1260. doi: 10.1016/j.mayocp.2017.04.006.</mixed-citation></ref><ref id="B12"><mixed-citation>Coresh J., Heerspink H.J.L., Sang Y., Matsushita K., Arnlov J., Astor B.C., Black C., Brunskill N.J., Carrero J.J., Feldman H.I., Fox C.S., Inker L.A., Ishani A., Ito S., Jassal S., Konta T., Polkinghorne&amp;nbsp;K., Romundstad S., Solbu M.D., Stempniewicz N., Stengel B., Tonelli M., Umesawa&amp;nbsp;M., Waikar S.S., Wen C.P., Wetzels J.F.M., Woodward M., Grams M.E., Kovesdy C.P., Levey A.S., Gansevoort R.T. 2019. Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. The Lancet Diabetes &amp;amp; Endocrinology. 7: 115&amp;ndash;127. doi: 10.1016/S2213-8587(18)30313-9.</mixed-citation></ref><ref id="B13"><mixed-citation>Coresh J., 2017. Update on the Burden of CKD. Journal of the American Society of Nephrology. 28: 1020&amp;ndash;1022. doi: 10.1681/ASN.2016121374.</mixed-citation></ref><ref id="B14"><mixed-citation>Costanzo M.R. 2020. The Cardiorenal Syndrome in Heart Failure. Heart Failure Clinics. 16: 81&amp;ndash;97. doi: 10.1016/j.hfc.2019.08.010.</mixed-citation></ref><ref id="B15"><mixed-citation>Cowger J.A., Radjef R. 2018. Advanced heart failure therapies andcardiorenal syndrome. Advances in Chronic Kidney Disease. 25: 443&amp;ndash;453 doi: 10.1053/j.ackd.2018.08.012.</mixed-citation></ref><ref id="B16"><mixed-citation>Daenen K., Andries A., Mekahli D., Van Schepdael A., Jouret F., Bammens B. 2019. Oxidative stress in chronic kidney disease. Pediatric nephrology. 34 (6): 975&amp;ndash;991. doi: 10.1007/s00467-018-4005-4.</mixed-citation></ref><ref id="B17"><mixed-citation>Dhaun N., Goddard J., Webb D.J. 2006. The Endothelin System and Its Antagonism in Chronic Kidney Disease. JASN. 17 (4): 943&amp;ndash;955. doi: 10.1681/ASN.2005121256.</mixed-citation></ref><ref id="B18"><mixed-citation>Dincer N., Dagel T., Afsar B., Covic A., Ortiz A., Kanbay M. 2019. The effect of chronic kidney disease on lipid metabolism. InternationalUrology and Nephrology. 51: 265&amp;ndash;277. doi: 10.1007/s11255-018-2047-y.</mixed-citation></ref><ref id="B19"><mixed-citation>Djudjaj S., Boor P. 2019. Cellular and molecular mechanisms of kidney fibrosis.&amp;nbsp;Molecular Aspects of Medicine. 65: 16&amp;ndash;36. doi: 10.1016/j.mam.2018.06.002.</mixed-citation></ref><ref id="B20"><mixed-citation>Duni A., Liakopoulos V., Rapsomanikis K.P., Dounousi E. 2017. Chronic Kidney Disease and Disproportionally Increased Cardiovascular Damage: Does Oxidative Stress Explain the Burden? Oxidative Medicine and Cellular Longevity. 2017: 9036450. doi: 10.1155/2017/9036450.</mixed-citation></ref><ref id="B21"><mixed-citation>Efremova O.A., Kamyshnikova L.A., Veysalov S.E., Sviridova M.S., Obolonkova N.I., Maslennikov&amp;nbsp;A.A., Wuraola M. 2020. Imbalance in the oxidative stress system &amp;ndash; antioxidant protection in patients with chronic pyelonephritis depending on the course of the disease. International journal of pharmaceutical research. 12: 1086&amp;ndash;1091. doi: 10.31838/ijpr/2020.SP1.161</mixed-citation></ref><ref id="B22"><mixed-citation>Efremova O.A., Kamyshnikovа L.A., Weisalov S.E., Sviridova M.S. 2019. Parameters of structural and functional condition of the heart and great vessels in patients with chronic pyelonephritis, depends on the course of the disease. Belgorod State University Scientific Bulletin. Medicine. Pharmacy series. 42 (4): 375&amp;ndash;389 (in Russ., English abstract). doi 10.18413/2075-4728-2019-42-4-375-389</mixed-citation></ref><ref id="B23"><mixed-citation>Fan P.C., Chang C.H., Chen Y.C. 2018. Biomarkers for acute cardio-renal syndrome. Nephrology (Carlton). 23 (l4): 68&amp;ndash;71. doi: 10.1111/nep.13473. PMID: 30298648.</mixed-citation></ref><ref id="B24"><mixed-citation>Fu S., Zhao S., Ye P., Luo L. 2018. Biomarkers in cardiorenal syn-dromes. Bio Med Research International. 9617363. doi: 10.1155/2018/9617363.</mixed-citation></ref><ref id="B25"><mixed-citation>Fujii H., Kono K., Nishi S. 2019. Characteristics of coronary artery disease in chronic kidney disease. Journal of Clinical &amp;amp; Experimental Nephrology. 23: 725&amp;ndash;732. doi: 10.1007/s10157-019-01718-5.</mixed-citation></ref><ref id="B26"><mixed-citation>Gonzalez-Vicente A., Hong N.J., Garvin J.L. 2019. Effects of reactive oxygen species on renal tubular transport. The American Journal of Physiology: Renal Physiology. 317 (2): F444-F455. doi: 10.1152/ajprenal.00604.2018.</mixed-citation></ref><ref id="B27"><mixed-citation>Grande D., Terlizzese P., Iacoviello M. 2017. Role of imaging in theevaluation of renal dysfunction in heart failure patients. World Journal of Nephrology. 6: 123&amp;ndash;131. doi: 10.5527/wjn.v6.i3.123.</mixed-citation></ref><ref id="B28"><mixed-citation>Han X., Zhang S., Chen Z., Adhikari B.K., Zhang Y., Zhang J., Sun J., Wang Y. 2020. Cardiac biomarkers of heart failure in chronic kidney disease. Clinica Chimica Acta. 510: 298&amp;ndash;310. doi: 10.1016/j.cca.2020.07.040.</mixed-citation></ref><ref id="B29"><mixed-citation>Harrison J.C., Smart S.D.G., Besley E.M.H., Kelly J.R., Read M.I., Yao Y., Sammut I.A. 2020. A Clinically Relevant Functional Model of Type-2 Cardio-Renal Syndrome with Paraventricular Changes consequent to Chronic Ischaemic Heart Failure. Scientific Reports. 10: 1261. doi: 10.1038/s41598-020-58071-x.</mixed-citation></ref><ref id="B30"><mixed-citation>Huang Y.M., Li W.W., Wu J., Han M., Li B.H. The diagnosticvalue of circulating microRNAs in heart failure. Experimental and Thera-peutic Medicine. 2019; 17: 1985&amp;ndash;2003. doi: 10.3892/etm.2019.7177.</mixed-citation></ref><ref id="B31"><mixed-citation>Hur J., Choi B.W. 2017. Cardiac CT imaging for ischemic stroke: Cur-rent and evolving clinical applications. Radiology. 283: 14&amp;ndash;28. doi: 10.1148/radiol.2016152043.</mixed-citation></ref><ref id="B32"><mixed-citation>Ishigami J., Cowan L.T., Demmer R.T., Grams M.E., Lutsey P.L., Carrero J.J., Coresh J., Matsushita K. 2020. Incident Hospitalization with Major Cardiovascular Diseases and Subsequent Risk of ESKD: Implications for Cardiorenal Syndrome. JASN. 31 (2): 405&amp;ndash;414. doi: 10.1681/ASN.2019060574.</mixed-citation></ref><ref id="B33"><mixed-citation>Jing W., Vaziri N.D., Nunes A., Suematsu Y., Farzaneh T., Khazaeli M., Moradi H. 2017. LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. American Journal of Translational Research. 9: 5473&amp;ndash;5484. PMID: 29312499; PMCID: PMC5752897.</mixed-citation></ref><ref id="B34"><mixed-citation>Junho C.V.C., Caio-Silva W., Trentin-Sonoda M., Carneiro-Ramos M.S. 2020. An Overview of the Role of Calcium/Calmodulin-Dependent Protein Kinase in Cardiorenal Syndrome. Frontiers in Physiology. 11: 735. doi: 10.3389/fphys.2020.00735.</mixed-citation></ref><ref id="B35"><mixed-citation>Kamyshnikova L.A., Efremova O.A., Pivovar R.S. 2017. Features of cardiorenal relationship at patients with the chronic disease of kidneys. The current state of the problem. Belgorod State University Scientific bulletin. Medicine. Pharmacy. 5 (254): 13&amp;ndash;21 (in Russ., English abstract).</mixed-citation></ref><ref id="B36"><mixed-citation>Kumar U., Wettersten N., Garimella P.S. 2019. Cardiorenal Syndrome: Pathophysiology. Cardiology Clinics. 37 (3): 251&amp;ndash;265. doi: 10.1016/j.ccl.2019.04.001.</mixed-citation></ref><ref id="B37"><mixed-citation>Li L., Lai E.Y., Luo Z., Solis G., Griendling K.K., Taylor W.R., Jose P.A., Wellstein A., Welch W.J., Wilcox C.S. 2017. Superoxide and hydrogen peroxide counterregulate myogenic contractions in renal afferent arterioles from a mouse model of chronic kidney disease. Kidney International. 92:&amp;nbsp;625&amp;ndash;633. doi: 10.1016/j.kint.2017.02.009.</mixed-citation></ref><ref id="B38"><mixed-citation>Liakopoulos V., Roumeliotis S., Zarogiannis S., Eleftheriadis T., Mertens P.R. 2019. Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 32 (1): 58&amp;ndash;71. doi: 10.1111/sdi.12745.</mixed-citation></ref><ref id="B39"><mixed-citation>Liu H.J., Liu B. 2018. Inhibition of MicroRNA-23 contributes to the isoflurane-mediated cardioprotection against oxidative stress. Cardiovascular Toxicology. 18: 450&amp;ndash;458. doi: 10.1007/s12012-018-9455-1.</mixed-citation></ref><ref id="B40"><mixed-citation>Lu W., Booz G.W., Fan F., Wang Y., Roman R.J. 2018. Oxidative stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies.&amp;nbsp;Frontiers in Physiology. 16: 105. doi: 10.3389/fphys.2018.00105.</mixed-citation></ref><ref id="B41"><mixed-citation>Magaye R.R., Savira F., Hua Y., Kelly D.J., Reid C., Flynn B., Liew D., Wang B.H. 2019. The role of dihydrosphingolipids in disease. Cellular and Molecular Life Sciences. 76 (6): 1107&amp;ndash;1134. doi: 10.1007/s00018-018-2984-8.</mixed-citation></ref><ref id="B42"><mixed-citation>McCullough P.A. 2021. Anemia of cardiorenal syndrome. Kidney International Supplements. 11 (1): 35&amp;ndash;45. doi: 10.1016/j.kisu.2020.12.001.</mixed-citation></ref><ref id="B43"><mixed-citation>Medvedeva M.V. 2021. Associations of rs2305948 and rs1870377 polymorphic variants of the vascular endothelial growth factor receptor type 2 (KDR) gene with the risk of coronary heart disease. Research Results in Biomedicine. 7 (1): 32&amp;ndash;43 (in Russian). doi: 10.18413/2658-6533-2020-7-1-0-3</mixed-citation></ref><ref id="B44"><mixed-citation>Melnyk A.А. Cardiorenal syndrome: diagnosis and treatment. Pochki. 2017. 6: 2&amp;ndash;14 (in Russ., English abstract).</mixed-citation></ref><ref id="B45"><mixed-citation>Nallu A., Sharma S., Ramezani A., Muralidharan J., Raj D. 2017. Gutmicrobiome in chronic kidney disease: Challenges and opportunities.Translational Research. 179: 24&amp;ndash;37. doi: 10.1016/j.trsl.2016.04.007.</mixed-citation></ref><ref id="B46"><mixed-citation>Orvalho J.S., Cowgill L.D. 2017. Cardiorenal Syndrome: Diagnosis and Management. Veterinary Clinics of North America: Small Animal Practice. 47 (5): 1083&amp;ndash;1102. doi: 10.1016/j.cvsm.2017.05.004.</mixed-citation></ref><ref id="B47"><mixed-citation>Pavlakou P., Liakopoulos V., Eleftheriadis T., Mitsis M., Dounousi E. 2017. Oxidative Stress and Acute Kidney Injury in Critical Illness: Pathophysiologic Mechanisms-Biomarkers-Interventions, and Future Perspectives. Oxidative Medicine and Cellular Longevity. 2017: 6193694. doi: 10.1155/2017/6193694.</mixed-citation></ref><ref id="B48"><mixed-citation>Peterson S.J., Choudhary A., Kalsi A.K., Zhao Sh., Alex R., Abraham N.G. 2020. OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention. Diagnostics. 10&amp;nbsp;(11): 976. doi: 10.3390/diagnostics10110976.</mixed-citation></ref><ref id="B49"><mixed-citation>Petra E., Zoidakis J., Vlahou A. 2019. Protein biomarkers for cardiorenal syndrome. Expert Rev Proteomics. 16 (4): 325&amp;ndash;336. doi: 10.1080/14789450.2019.1592682.</mixed-citation></ref><ref id="B50"><mixed-citation>Raina R., Nair N., Chakraborty R., Nemer L., Dasgupta R., Varian K. 2020. An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome. Cardiology Research. 11 (2): 76&amp;ndash;88. doi: 10.14740/cr955.</mixed-citation></ref><ref id="B51"><mixed-citation>Rangaswami J., Bhalla V., Blair J.E.A., Chang T.I., Costa S., Lentine K.L., Lerma E.V., Mezue K., Molitch M., Mullens W., Ronco C., Tang W.H.W., McCullough P.A. 2019. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement from the American Heart Association. Circulation. 139&amp;nbsp;(16): e840-e878. doi: 10.1161/CIR.0000000000000664.</mixed-citation></ref><ref id="B52"><mixed-citation>Ronco C., Bellasi A., Di Lullo L. 2018. Cardiorenal Syndrome: An Overview. Adv. Chronic. Kidney Dis. 25 (5): 382&amp;ndash;390. doi: 10.1053/j.ackd.2018.08.004.</mixed-citation></ref><ref id="B53"><mixed-citation>Ronco C., Di Lullo L. 2014. Cardiorenal syndrome. Heart Failure Clinics. 10: 251&amp;ndash;280. doi: 10.1016/j.hfc.2013.12.003.</mixed-citation></ref><ref id="B54"><mixed-citation>Roumeliotis S., Eleftheriadis T., Liakopoulos V. 2019. Is oxidative stress an issue in peritoneal dialysis? Semin Dial. 32 (5): 463&amp;ndash;466. doi: 10.1111/sdi.12818.</mixed-citation></ref><ref id="B55"><mixed-citation>Rubinstein J., Sanford D. 2019. Treatment of cardiorenal syndrome. Cardiology Clinics. 37: 267&amp;ndash;273. doi: 10.1016/j.ccl.2019.04.002.</mixed-citation></ref><ref id="B56"><mixed-citation>Sagoo M.K., Gnudi L. 2018. Diabetic nephropathy: Is there a role for oxidative stress?&amp;nbsp;Free Radical Biology and Medicine. 20: 50&amp;ndash;63. doi: 10.1016/j.freeradbiomed.2017.12.040.</mixed-citation></ref><ref id="B57"><mixed-citation>Saito Yo. 2020. The role of the PlGF/Flt-1 signaling pathway in the cardiorenal connection, Journal of Molecular and Cellular Cardiology. 151: 106&amp;ndash;112. doi: 10.1016/j.yjmcc.2020.10.001.</mixed-citation></ref><ref id="B58"><mixed-citation>S&amp;aacute;rk&amp;ouml;zy M., Kov&amp;aacute;cs Z.Z.A., Kov&amp;aacute;cs M.G., G&amp;aacute;sp&amp;aacute;r R., Szűcs G., Dux L. 2018. Mechanisms and Modulation of Oxidative/Nitrative Stress in Type 4 Cardio-Renal Syndrome and Renal Sarcopenia. Frontiers in Physiology. 9: 1648. doi: 10.3389/fphys.2018.01648.</mixed-citation></ref><ref id="B59"><mixed-citation>Savira F., Kompa A.R., Edgley A.J., Jucker B.M., Willette R.N., Kelly D.J., Wang B.H. 2020 RE: ASK1, a new target in treating cardiorenal syndrome (CRS). International Journal of Cardiology. 316: 207. doi: 10.1016/j.ijcard.2020.05.050.</mixed-citation></ref><ref id="B60"><mixed-citation>Savira F., Magaye R., Liew D., Reid C., Kelly D.J., Kompa A.R., Sangaralingham S.J., Burnett J.C. Jr., Kaye D., Wang B.H. 2020. Cardiorenal syndrome: multi-organ dysfunction involving the heart, kidney and vasculature. British Journal of Pharmacology. 177&amp;nbsp;(13): 2906&amp;ndash;2922. doi: 10.1111/bph.15065.</mixed-citation></ref><ref id="B61"><mixed-citation>Schei J., Fuskev&amp;aring;g O.M., Stefansson V.T.N., Solbu M.D., Jenssen T.G., Eriksen B.O., Melsom T. 2017. Urinary markers of oxidative stress Are Associated with Albuminuria but Not GFR Decline. Kidney International Reports. 3: 573&amp;ndash;582. doi: 10.1016/j.ekir.2017.11.020.</mixed-citation></ref><ref id="B62"><mixed-citation>Seliger S. 2020. The Cardiorenal Syndrome: Mechanistic Insights and Prognostication with Soluble Biomarkers. Current Cardiology Reports. 22: 114. doi: 10.1007/s11886-020-01360-8.</mixed-citation></ref><ref id="B63"><mixed-citation>Takahama H., Kitakaze M. 2017. Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. Am. J. Physiol. Heart. Circ. Physiol. 313 (4): H715&amp;ndash;H721. doi: 10.1152/ajpheart.00215.2017.</mixed-citation></ref><ref id="B64"><mixed-citation>Uduman J. 2018. Epidemiology of Cardiorenal Syndrome. Advances in Chronic Kidney Disease. 25 (5): 391&amp;ndash;399. doi: 10.1053/j.ackd.2018.08.009.</mixed-citation></ref><ref id="B65"><mixed-citation>Vakulenko L.I. 2019. 24-hour blood pressure profile in children with chronic pyelonephritis and chronic kidney disease stages I&amp;ndash;III. Počki. 8 (3): 139&amp;ndash;145. doi: 10.22141/2307-1257.8.3.2019.176451</mixed-citation></ref><ref id="B66"><mixed-citation>Vamos M., Nyolczas N., Bari Z., Bogyi P., Muk B., Szabo B., Ancsin B., Kiss R.G., Duray G.Z. 2018. Refined heart failure detection algorithm for improved clinical reliability of OptiVol alerts in CRT-D recipients. Cardiol. J. 25 (2): 236&amp;ndash;244. doi: 10.5603/CJ.a2017.0077.</mixed-citation></ref><ref id="B67"><mixed-citation>Virz&amp;igrave; G.M., de Cal M., Day S., Brocca A., Cruz D.N., Castellani C., Cantaluppi V., Bolin C., Fedrigo M., Thiene G., Valente M., Angelini A., Vescovo G., Ronco C. 2015. Pro-apoptotic effects of plasma from patients with cardiorenal syndrome on human tubular cells. American Journal of Nephrology. 41: 474&amp;ndash;484. doi: 10.1159/000438459.</mixed-citation></ref><ref id="B68"><mixed-citation>Wang Y., Zhao R., Liu D., Deng W., Xu G., Liu W., Rong J., Long X., Ge J., Shi B. 2018. Exosomes Derived from miR-214-Enriched Bone Marrow-Derived Mesenchymal Stem Cells Regulate Oxidative Damage in Cardiac Stem Cells by Targeting CaMKII. Oxid. Med. Cell. Longev. 2018: 4971261. doi: 10.1155/2018/4971261.</mixed-citation></ref><ref id="B69"><mixed-citation>Wong M.H., Samal A.B., Lee M., Vlach J., Novikov N., Niedziela-Majka A., Feng J.Y., Koltun D.O., Brendza K.M., Kwon H.J., Schultz B.E., Sakowicz R., Saad J.S., Papalia G.A. 2019. The KN-93 molecule inhibits Calcium/Calmodulin-dependent protein kinase II (CaMKII) activity by binding to Ca2+/CaM. Journal of Molecular Biology. 431: 1440&amp;ndash;1459. doi: 10.1016/j.jmb.2019.02.001.</mixed-citation></ref><ref id="B70"><mixed-citation>Zhang S., Tan X., Chen Y., Zhang X. 2017. Postconditioning protects renal fibrosis by attenuation oxidative stress-induced mitochondrial injury. The Nephrology Dialysis Transplantation.</mixed-citation></ref><ref id="B71"><mixed-citation>32: 1628&amp;ndash;1636. doi: 10.1093/ndt/gfw469.</mixed-citation></ref></ref-list></back></article>